Developing Innovative Therapeutics for Ocular Diseases

Global leading candidate in Phase 2b for the treatment of adenoviral conjunctivitis.

Research & Development

Enhancing Lives Through Better Vision

Okogen, founded in 2015, is a clinical stage ophthalmic specialty biotechnology company. We are exclusively focused on developing the leading treatment of adenoviral conjunctivitis.

With acute conjunctivitis representing 1% of all primary care visits in the US, we see a significant need and opportunity.

  • Up to 3 million new cases of adenoviral conjunctivitis per year in the US.
  • Acute conjunctivitis accounts for 35% to 50% of all eye diseases examined by general practitioners.
  • There are currently no approved therapeutics available to treat adenoviral conjunctivitis today.
Meet the Team

Latest News & Press

View All News
Press Release

Okogen, Inc., Announces Ophthalmology Industry Veteran Joshua Moriarty as New Chief Executive Officer

March 8, 2022
Read More
Press Release

Safe, Effective and Dose Responsive Anti-Viral Activity of OKG-0301 in Patients with Acute Adenoviral Conjunctivitis–Phase 2 Interim Analysis Results from RUBY Clinical Trial

April 29, 2021
Read More
Press Release

Okogen Initiates Phase 2 Clinical Trial (RUBY) of OKG-0301 in Patients

January 31, 2019
Read More

© 2021 Okogen, Inc. All Rights Reserved

United States

Okogen, Inc.
332 Encinitas Blvd. Suite 102
Encinitas, CA 92024, USA

Australia

Okogen Pty Ltd
Level 9, 31 Queen St
Melbourne, VIC 3000 AUS

Main Menu